Ginkgo Bioworks looks past Covid tests for its next source of revenue

Two years into the pandemic, Ginkgo Bioworks is still relying on Covid-19 testing for most of its revenue — and as its partners scale back testing budgets and operations, it’s unclear how steady that stream of income will be.